1 effect was augmented by desferroioxamine, an iron chelating agent.

2 rable with deferoxamine, a clinically useful iron-chelating agent.

3 red when choosing the appropriate dose of an iron-chelating agent.

4 evaluation both as a potential orally active iron-chelating agent and as a parenteral iron chelator.

5  ideal clinical setting, patient population, iron chelating agent, and dosing regimen.

6 AcnD activity was lost after incubation with iron-chelating agents, and no AcnD activity was observed

7 rk contrast to this behavior, addition of an iron chelating agent (citrate) to the protein solution r

8                       Deferoxamine (DFO), an iron-chelating agent clinically used to treat iron toxic

9                           The actual role of iron chelating agents may be to promote a long enough su

10               ADO appeared less sensitive to iron chelating agents or transition metal exposure than

11                       Well-known as specific iron chelating agents produced by bacteria, it is shown

12 is via the secretion of low-molecular-weight iron-chelating agents (siderophores).

13               These results demonstrate that iron-chelating agents such as PCIH may be of benefit in

14 ric oxide and free-radical formation, use of iron chelating agents, the potential role of hypoxia-ind